Oral decitabine and cedazuridine (ASTX727) granted Orphan Drug Designation (ODD) by the European Commission for the treatment of Acute Myeloid Leukaem

Oral decitabine and cedazuridine (ASTX727) granted Orphan Drug Designation (ODD) by the European Commission for the treatment of Acute Myeloid Leukaemia (AML)LONDON, UK, 6th January 2022 – Otsuka Pharmaceutical Europe Ltd. (“Otsuka”) and Astex Pharmaceuticals, Inc. (“Astex”) announce to...

Related Keywords

London ,City Of ,United Kingdom ,Canada ,Australia ,Japan ,Tokyo ,United States ,France ,French ,American ,British ,Otsuka Europe ,Brandy Hodge ,Alison Ross ,European Commission ,Otsuka Pharmaceutical Company Ltd ,Taiho Oncology Inc ,Otsuka Pharmaceutical Co ,Taiho Pharma Canada Inc ,European Union ,Otsuka Pharmaceutical Europe Ltd ,International Prognostic Scoring System ,Otsuka Holdings Co Ltd ,Astex Pharmaceuticals Inc ,Orphan Drug Designation ,Acute Myeloid Leukaemia ,Otsuka Pharmaceutical Europe ,Astex Pharmaceuticals ,Chief Medical Officer ,Lancet Haematology ,Taiho Oncology ,Taiho Pharma Canada ,Acute Myeloid Leukemia ,Otsuka Pharmaceutical ,Pharmaceutical Europe ,Otsuka Pharmaceutical Company ,